Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

Must have received: anti-tumor treatment

thrombocytopenia due to anti-tumor treatments (e.g., chemotherapy, immunotherapy, targeted therapy, and radiotherapy)

Cannot have received: platelet transfusion or blood products containing platelet components

No transfusion of platelets or blood products containing platelet components within 72 hours prior to investigational product administration.

Cannot have received: thrombopoietin-stimulating drugs (recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11), romiplostim, eltrombopag, hetrombopag, leucogen tablets, aminopeptidase tablets, caffeic acid tablets)

Use of thrombopoietin-stimulating drugs within 7 days prior to receiving the investigational product, including recombinant human thrombopoietin (rhTPO), recombinant human interleukin-11 (rhIL-11), romiplostim, eltrombopag, hetrombopag, leucogen tablets, aminopeptidase tablets, and caffeic acid tablets.

Cannot have received: anticoagulant drugs and/or antiplatelet therapy (vitamin K antagonists, low molecular weight heparin, factor Xa inhibitors (e.g., rivaroxaban), thrombin inhibitors, aspirin)

Exception: except for minimal heparin use for catheter locking

Use of anticoagulant drugs within 7 days before screening, including vitamin K antagonists, low molecular weight heparin (except for minimal heparin use for catheter locking), factor Xa inhibitors (e.g., rivaroxaban), thrombin inhibitors, and/or antiplatelet therapy (e.g., aspirin).

Cannot have received: investigational product with a similar mechanism of action

Exception: except for observational, non-interventional clinical trials, or the follow-up period of an interventional clinical trial

Use of any investigational product with a similar mechanism of action within 4 weeks prior to administration of the investigational product, or current participation in another clinical trial (except for observational, non-interventional clinical trials, or the follow-up period of an interventional clinical trial).